AMAG Pharmaceuticals Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2014
New white paper documents Lilly's philanthropic effort to expand access to multidrug-resistant tuberculosis medicines
Plans to Payout Approximately 60 Percent of Adjusted Net Income on Average to Shareholders Through 2018
QUEENSLAND, Australia, Oct.
Universal Health Services, Inc. Reports Financial Results For The Three And Nine Months Ended September 30, 2014
Consolidated Results of Operations, As Reported - Three and nine-month periods ended September 30, 2014 and 2013:
KING OF PRUSSIA, Pa.
Assistance Programs, Dividends, Campaigns, Drug Recommendations, and Research Collaborations - Research Reports on Duke Energy, Exelon, Marriott, Vertex and AstraZeneca
Editor Note: For more information about this release, please scroll to bottom.
NEW YORK, October 27, 2014
Amgen's Third Quarter 2014 Revenues Increased 6 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 19 Percent To $2.30
Third Quarter 2014 GAAP EPS Were $1.61
THOUSAND OAKS, Calif., Oct.
CUPERTINO, Calif., Oct.